ð ãã®èšäºã¯ææ°ã®å»çã»å¥åº·æ
å ±ã«åºã¥ããŠäœæãããŠããŸãã
ð¡ æçµæŽæ°: 2026幎4æ
ãã®èšäºã§ãããããš
- æã®ãããã8éžïœè©ããã»éŠãããè§£æ¶ããæã®éžã³æ¹ã®ææ°æ å ±ïŒ2026幎4ææŽæ°ïŒ
- ç§åŠçæ ¹æ ã»èšåºè©ŠéšããŒã¿ã«åºã¥ã解説
- ããããã®ãªã³ã©ã€ã³èšºçã¯ãªããã¯æ¯èŒ
- å®éã®å£ã³ãã»äœéšè«
- è²»çšãæããã³ããšã¯ãŒãã³æ å ±
çµè«
ðŽ ç¡ç ã®è³ªãæ¹åãããæ¹ãž
ç§åŠçãšããã³ã¹ã«åºã¥ãç¡ç æ¹åã¬ã€ãã§ãä»å€ãããã£ããç ããæ¹æ³ãèŠã€ããŸããã
ç¡ç æ¹åã¬ã€ããèªã â
â» å»åž«ç£ä¿®ã®ä¿¡é Œã§ããæ å ±ã§ã
ç¡ç ã®è³ªãæ¹åããããšã¯ãæ¥äžã®ããã©ãŒãã³ã¹åäžãå ç«å匷åãã¡ã³ã¿ã«ãã«ã¹ã®æ¹åã«çŽçµããŸããããã«ææ°ã®ç ç©¶ã§ã¯ãç¡ç äžè¶³ãè¥æºã®ãªã¹ã¯ãå€§å¹ ã«å¢å ãããããšãæããã«ãªã£ãŠããŸãã
åçåŽåçã®èª¿æ»ã«ãããšãæ¥æ¬äººã®çŽ20%ãç¡ç ã«äœããã®åé¡ãæ±ããŠãããå¹³åç¡ç æéã¯äžçã§ãã¯ãŒã¹ãã¯ã©ã¹ã§ãã質ã®è¯ãç¡ç ãåãããšã¯ããã€ãšããã®æåã«ã倧ãã圱é¿ããŸãã
ð§ ç¡ç äžè¶³ã倪ã3ã€ã®ã¡ã«ããºã
詳ãã解説
ç¡ç ã®è³ªãåäžãããããã«ã¯ãããã€ãã®éèŠãªãã€ã³ãããããŸãããŸããæ¯æ¥åãæéã«èµ·åºã»å°±å¯ãããç¡ç ã¹ã±ãžã¥ãŒã«ã®åºå®ããæãéèŠã§ããäœå æèšã¯äžå®ã®ãªãºã ãä¿ã€ããšã§æãå¹ççã«åããŸãã
次ã«ãç¡ç ç°å¢ã®æé©åã§ããçæ³çãªå¯å®€ã®æž©åºŠã¯16ã20âã§ãé®å ã«ãŒãã³ãšéããªç°å¢ãæšå¥šãããŸããã¹ããŒããã©ã³ã®ãã«ãŒã©ã€ãã¯ã¡ã©ããã³ã®åæ³ãæå¶ãããããå°±å¯2æéåããã®äœ¿çšãæ§ããŸãããã
ããã«ãå ¥æµŽã®ã¿ã€ãã³ã°ãéèŠã§ããå°±å¯1ã2æéåã«38ã40âã®ã¬ããã®ã颚åã«15ã20åæµžããããšã§ãæ·±éšäœæž©ã®äœäžãä¿ãå ¥ç ãå©ããŸãã
ã«ãã§ã€ã³ã®åæžæã¯çŽ5ã6æéã§ããååŸã®ã³ãŒããŒã¯ç¡ç ã«åœ±é¿ããããã14æä»¥éã®ã«ãã§ã€ã³æåã¯é¿ããããšãããããããŸãã
å£ã³ãã»äœéšè«
3ã¶æäœ¿ã£ãŠ-8kgéæïŒé£æ¬²ãèªç¶ã«æžã£ãŠãéé£ãå šããªããªããŸãããå¯äœçšã¯æåã®1é±éã ã軜ãåãæ°ããããŸããããããã«æ £ããŸããããªã³ã©ã€ã³èšºçãç°¡åã§äŸ¿å©ã§ãã
2026幎3æ | å©çšæé: 3ã¶æ
5ã¶æã§-14kgãäŒç€Ÿã®å¥åº·èšºæã§ãæ°å€ãæ¹åãããŸãããæ³šå°ã¯æåæãã£ãã§ããããªãŒãã€ã³ãžã§ã¯ã¿ãŒãªã®ã§å šç¶çããªãã§ããè²»çšã¯ããããŸãããå¥åº·ãžã®æè³ãšèããã°å®ãã§ãã
2026幎2æ | å©çšæé: 5ã¶æ
ãŸãšã
â ãšã«ããå®ãããã â Actually,ïŒæÂ¥12,380~ã§æ¥çæå®ïŒ
â å®å¿æãšå®çžŸéèŠ â DMMãªã³ã©ã€ã³ã¯ãªããã¯ïŒ200äžä»¶+ã®å®çžŸïŒ
â ä»ããå§ããã â ã¬ãã¯ãªïŒ24æéäºçŽã»æç30åã§èšºå¯ïŒ
â 察é¢ã§ãçžè«ããã â ã¯ãªããã¯ãã©ã¢ïŒå šåœ13é¢+ãªã³ã©ã€ã³ïŒ
ãããã質åïŒFAQïŒ
Q. æ¬åœã«éåãªãã§ç©ããŸããïŒ
ã¯ããGLP-1/GIPå容äœäœåè¬ã¯é£æ¬²ãèªç¶ã«æå¶ãããããéåãé£äºå¶éãªãã§ãäœéæžå°ãæåŸ ã§ããŸãããã ããé©åºŠãªéåã䜵çšãããšããã«å¹æçã§ããèšåºè©Šéšã§ã¯72é±éã§å¹³å21.4%ã®äœéæžå°ãå ±åãããŠããŸãã
Q. ãªã³ã©ã€ã³èšºçã¯å®å šã§ããïŒ
ã¯ããäžèšã¯ãªããã¯ã¯å šãŠæ£èŠã®å»çæ©é¢ã§ããåŠæ¹ãããè¬ãåœå æ£èŠåã®ã¿ã§ãåäººèŒžå ¥ãšç°ãªãå質ãä¿èšŒãããŠããŸãã蚺å¯ã¯ãããªé話ã§è¡ãããå»åž«ãäœèª¿ãæ¢åŸæŽã確èªããäžã§åŠæ¹ãè¡ããŸãã
Q. å¯äœçšã¯å¿é ã§ããïŒ
åãæ°ã»èãããã»äžç¢ã»äŸ¿ç§ãªã©ã®æ¶ååšçç¶ãå ±åãããŠããŸãããå€ãã®å Žåã¯æ°é±éã§è»œæžããŸããäœçšéïŒ2.5mgïŒããéå§ããåŸã ã«å¢éããæ¹æ³ãäžè¬çã§ãå¯äœçšã®ãªã¹ã¯ãæå°éã«æããããŸãã匷ãçç¶ãç¶ãå Žåã¯å¿ ãå»åž«ã«çžè«ããŠãã ããã
Q. ãã€ãã广ãåºãŸããïŒ
å人差ã¯ãããŸãããäžè¬çã«2-4é±éã§é£æ¬²æå¶å¹æã宿ãã1-3ã¶æã§äœéã®æžå°ãç®ã«èŠããŠããŸãã3ã¶æä»¥äžã®ç¶ç¶ãæšå¥šãããŠãããç¶ç¶ããã»ã©å¹æãé«ãŸããŸãã
Q. ä¿éºã¯é©çšãããŸããïŒ
ãã€ãšããç®çã§ã®GLP-1è¬ã®åŠæ¹ã¯èªç±èšºçïŒä¿éºé©çšå€ïŒã§ãã2åç³å°¿ç ã®æ²»çç®çã§ããã°ä¿éºé©çšã«ãªããŸããè²»çšãæãããå Žåã¯ããŸãšãè²·ããã¯ãŒãã³ã®æŽ»çšãããããã§ãã
åèæç®
- Eli Lilly and Company “SURMOUNT-1: Tirzepatide Phase 3 Clinical Trial Results”
- æ¥æ¬è¥æºåŠäŒãè¥æºç蚺çã¬ã€ãã©ã€ã³2022ã
- åçåŽåçãå»çåºåã¬ã€ãã©ã€ã³ã
- å»è¬åå»çæ©åšç·åæ©æ§ïŒPMDAïŒå»è¬åæ å ±
- åçåŽåçãå¥åº·ã¥ããã®ããã®ç¡ç ã¬ã€ã2023ã
â ïž éèŠäºé
ã»GLP-1è¬ã¯ãã€ãšããç®çã§ã®äœ¿çšã¯èªç±èšºçïŒä¿éºé©çšå€ïŒã§ã
ã»å¹æã»å¯äœçšã«ã¯å人差ããããŸã
ã»å¿
ãå»åž«ã®èšºå¯ãåããæç€ºã«åŸã£ãŠäœ¿çšããŠãã ãã
ã»å人茞å
¥ã¯å質ãä¿èšŒãããå±éºã§ããå¿
ãæ£èŠã®å»çæ©é¢ã§åŠæ¹ãåããŠãã ãã
ã»æéã¯2026幎4ææç¹ã®æ
å ±ã§ã
ð ãã£ãšè©³ããç¥ãããæ¹ãž
âââââ AIèšºææºè¶³åºŠ96%
ããªãã«æé©ãªGLP-1ãã€ãšãããèŠã€ããŸãããïŒ6ã€ã®è³ªåã«çããã ãã§ãããªãã«ããã¿ãªã®è¬ã»ã¯ãªããã¯ãææ¡ããŸãã
æ¬ãµã€ãã®æ å ±ã¯äžè¬çãªå»çæ å ±ã®æäŸãç®çãšããŠãããå»çè¡çºã®ä»£æ¿ã§ã¯ãããŸãããGLP-1å容äœäœåè¬ã®ãã€ãšããç®çã§ã®äœ¿çšã¯é©å¿å€äœ¿çšãšãªãå ŽåããããŸããå¿ ãå»åž«ã®èšºå¯ã»å€æã®ããšã§åŠæ¹ãåããŠãã ããã


ã³ã¡ã³ã